IO Biotech, a clinical-stage biopharmaceutical company with a global footprint, is developing novel, immune-modulating cancer ... responses to a single epitope treatment. The ability to repress ...

BRB-002 was safe at all doses tested, with no SAEs reportedPhase 2 proof-of-concept study in patients with established atherosclerosis is expected to initiate in 1H 2025 PALO ALTO, Calif. and NEEDHAM, ...

It has been suggested that novel treatment options are needed that target both aspects of the disease. Evidence from basic and clinical studies suggests that testosterone has an immunomodulatory ...

Targeting T-cell activation has transformed the therapeutic landscape for patients with immune-mediated diseases ... and the beneficial effects of treatment typically don’t last forever.

The French company has seen its microbiome therapy for patients living with treatment-induced dysbiosis hit its endpoints.

as well as potential policy opportunities to improve the development of immunotherapies for cancer treatment. A National Academies of Sciences, Engineering, and Medicine planning committee will plan ...

Adimune Inc., a subsidiary of Aditxt Inc., has successfully completed preclinical studies for its antigen-specific gene therapy, ADI-100. BioWorld Science Dermatologic Endocrine/metabolic Immune ...

Aditxt, Inc.’s subsidiary, Adimune, Inc., has completed preclinical studies for its ADI-100 immune modulation therapy, positioning it for human trials targeting Type 1 Diabetes, Psoriasis ...

The US Food and Drug Administration has granted orphan drug designation (ODD) to Tempest Therapeutics' oral, selective ...

( MENAFN - EIN Presswire) market-grow.png" width="300" height="166" alt="Chronic Hepatitis B market Growth" /> David Correa Allied Market Research +1 800-792-5285 email us here Visit us on social ...

These patterns suggested distinct immune modulation roles within the plaque ... cancer patients undergoing immune checkpoint inhibitor treatment and offered a foundation for designing safer ...